Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71:209–49.

Article  Google Scholar 

Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6:e555–67.

Article  PubMed  Google Scholar 

Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015: Cancer Statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.

Article  PubMed  Google Scholar 

Fojo AT, Noonan A. RECIST: No longer the sharpest tool in the oncology clinical trials toolbox-reply to point. Cancer Res. 2012;72:5150–5150.

Article  CAS  PubMed  Google Scholar 

Xiao J, Li W, Huang Y, et al. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. BMC Cancer. 2021;21:282.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antoniotti C, Korn WM, Marmorino F, et al. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. Eur J Cancer. 2021;155:73–84.

Article  CAS  PubMed  Google Scholar 

Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.

Article  PubMed  PubMed Central  Google Scholar 

The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.

Article  Google Scholar 

Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I. NCCN guidelines insights: colon cancer, version 2.2018. J Natl Compr Cancer Netw. 2018;16(4):359–69.

Article  Google Scholar 

Bao X, Zhang H, Wu W, et al. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy. J Immunother Cancer. 2020;8:e001437.

Article  PubMed  PubMed Central  Google Scholar 

Yaeger R, Chatila WK, Lipsyc MD, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell. 2018;33:125-136.e3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie T, Cho YB, Wang K, et al. Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing. Genomics. 2014;104:234–41.

Article  CAS  PubMed  Google Scholar 

Zhao Z, Li W, Zhang X, et al. Correlation between TMB and MSI in patients with solid tumors. J Clin Oncol. 2020;38:e15169–e15169.

Article  Google Scholar 

Strickler JH, Hanks BA, Khasraw M. Tumor mutational burden as a predictor of immunotherapy response: is more always better? Clin Cancer Res. 2021;27:1236–41.

Article  CAS  PubMed  Google Scholar 

Heeke AL, Pishvaian MJ, Lynce F, et al. Prevalence of homologous recombination–related gene mutations across multiple cancer types. JCO Precis Oncol. 2018. 1–13.

Moretto R, Elliott A, Zhang J, et al. Homologous recombination deficiency alterations in colorectal cancer: clinical, molecular, and prognostic implications. JNCI J Natl Cancer Inst. 2021. djab169.

Zang Y, Dai C, Xu X, et al. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Cancer Med. 2019;8:4699–708.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Ng AW, Wu Y, Boot A, Covington KR, Gordenin DA, Bergstrom EN, Islam SA. The repertoire of mutational signatures in human cancer. BioRxiv. 2018;15:322859.

Google Scholar 

The ICGC/TCGA Pan-cancer analysis of whole genomes consortium. Pan-cancer analysis of whole genomes. Nature. 578:82–93.

Davies H, Glodzik D, Morganella S, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23:517–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niu B, Ye K, Zhang Q, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics. 2014;30:1015–6.

Article  CAS  PubMed  Google Scholar 

Denny JC, Collins FS. Precision medicine in 2030—seven ways to transform healthcare. Cell. 2021;184:1415–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alborelli I, Leonards K, Rothschild SI, et al. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer. J Pathol. 2020;250:19–29.

Article  CAS  PubMed  Google Scholar 

Telli ML, Timms KM, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22:3764–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30:1096–103.

Article  CAS  PubMed  Google Scholar 

Lanchbury J, Timms K, Reid J, Stronach E, Gutin A, Krivak T, Hennessy B, Paul J, Brown R, Nix R, Sangale Z. 3-biomarker HRD score versus individual biomarker (LOH, TAI, LST) scores in platinum treated serous ovarian cancer (SOC). Annals of Oncology. 2016 27:vi34.

Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Brithsh Journal of Cancer. 2012;107:1776–82.

Article  CAS  Google Scholar 

Smeby J, Kryeziu K, Berg KC, Eilertsen IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe RA, Sveen A. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine. 2020;1:59.

Google Scholar 

Moretto R, Elliott A, Zhang J, et al. Homologous recombination deficiency alterations in colorectal cancer: clinical, molecular, and prognostic implications. J Natl Cancer Inst. 2022;14(2):271–9.

Article  Google Scholar 

Takayama T, Miyanishi K, Hayashi T, et al. Colorectal cancer: genetics of development and metastasis. J Gastroenterol. 2006;41:185–92.

Article  CAS  PubMed  Google Scholar 

Fang T, Liang T, Wang Y, et al. Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2021;21:297.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang Z, Miao X, Zhao W. Identification of prognostic dosage-sensitive genes in colorectal cancer based on multi-omics. Front Genet. 2020;10:1310.

Article  PubMed  PubMed Central  Google Scholar